Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.

Lee HJ, Hur YK, Cho YD, Kim MG, Lee HT, Oh YK, Kim YB.

PLoS One. 2012;7(11):e50296. doi: 10.1371/journal.pone.0050296. Epub 2012 Nov 27.

2.

Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.

Cho H, Lee HJ, Heo YK, Cho Y, Gwon YD, Kim MG, Park KH, Oh YK, Kim YB.

PLoS One. 2014 Apr 23;9(4):e95961. doi: 10.1371/journal.pone.0095961. eCollection 2014.

3.

Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1.

Lee HJ, Park N, Cho HJ, Yoon JK, Van ND, Oh YK, Kim YB.

Vaccine. 2010 Feb 10;28(6):1613-9. doi: 10.1016/j.vaccine.2009.11.044. Epub 2009 Dec 2.

PMID:
19961961
4.

Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus.

Han SE, Kim MG, Lee S, Cho HJ, Byun Y, Kim S, Kim YB, Choi Y, Oh YK.

J Appl Toxicol. 2013 Dec;33(12):1474-83. doi: 10.1002/jat.2815. Epub 2012 Sep 14.

PMID:
22987290
5.

Preclinical pharmacokinetics and biodistribution of human papillomavirus DNA vaccine delivered in human endogenous retrovirus envelope-coated baculovirus vector.

Cho HJ, Lee S, Im S, Kim MG, Lee J, Lee HJ, Lee KH, Kim S, Kim YB, Oh YK.

Pharm Res. 2012 Feb;29(2):585-93. doi: 10.1007/s11095-011-0598-z. Epub 2011 Sep 23.

PMID:
21948385
6.

Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge.

Lee HJ, Cho H, Kim MG, Heo YK, Cho Y, Gwon YD, Park KH, Jin H, Kim J, Oh YK, Kim YB.

PLoS One. 2015 Mar 19;10(3):e0119408. doi: 10.1371/journal.pone.0119408. eCollection 2015.

7.

Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009.

Choi JY, Gwon YD, Kim JK, Cho YD, Heo YK, Cho HS, Choi TJ, Poo HR, Oh YK, Kim YB.

PLoS One. 2013 Nov 18;8(11):e80762. doi: 10.1371/journal.pone.0080762. eCollection 2013.

8.

Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.

Lee HJ, Yoon JK, Heo Y, Cho H, Cho Y, Gwon Y, Kim KC, Choi J, Lee JS, Oh YK, Kim YB.

J Microbiol. 2015 Jun;53(6):415-20. doi: 10.1007/s12275-015-5150-0. Epub 2015 May 30.

PMID:
26025174
9.

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group..

Hum Vaccin. 2009 Oct;5(10):705-19. Epub 2009 Oct 14.

PMID:
19684472
10.
11.

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.

J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.

12.

Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.

Diniz MO, Lasaro MO, Ertl HC, Ferreira LC.

Clin Vaccine Immunol. 2010 Oct;17(10):1576-83. doi: 10.1128/CVI.00264-10. Epub 2010 Aug 25.

13.

Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.

Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, Poo H.

Vaccine. 2012 May 9;30(22):3286-94. doi: 10.1016/j.vaccine.2012.03.009. Epub 2012 Mar 15.

PMID:
22426329
14.

Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1.

Gwon YD, Kim S, Cho Y, Heo Y, Cho H, Park K, Lee HJ, Choi J, Poo H, Kim YB.

PLoS One. 2016 May 5;11(5):e0154824. doi: 10.1371/journal.pone.0154824. eCollection 2016.

15.

Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.

Daemi A, Bolhassani A, Rafati S, Zahedifard F, Hosseinzadeh S, Doustdari F.

Immunol Lett. 2012 Dec 17;148(2):117-25. doi: 10.1016/j.imlet.2012.10.003. Epub 2012 Oct 17.

PMID:
23085605
17.

Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.

Zhang T, Xu Y, Qiao L, Wang Y, Wu X, Fan D, Peng Q, Xu X.

Vaccine. 2010 Apr 26;28(19):3479-87. doi: 10.1016/j.vaccine.2010.02.057. Epub 2010 Mar 6.

PMID:
20211219
18.

Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene.

Meshkat Z, Soleimanjahi H, Mirshahabi H, Meshkat M, Kheirandish M, Hassan ZM.

Iran J Immunol. 2011 Jun;8(2):65-75. doi: IJIv8i2A1.

PMID:
21705833
19.

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.

Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.

Cancer Immunol Immunother. 2004 Jul;53(7):642-50. Epub 2004 Feb 17.

PMID:
14985860
20.

Baculovirus as a PRRSV and PCV2 bivalent vaccine vector: baculovirus virions displaying simultaneously GP5 glycoprotein of PRRSV and capsid protein of PCV2.

Xu XG, Wang ZS, Zhang Q, Li ZC, Ding L, Li W, Wu HY, Chang CD, Lee LH, Tong DW, Liu HJ.

J Virol Methods. 2012 Feb;179(2):359-66. doi: 10.1016/j.jviromet.2011.11.023. Epub 2011 Dec 6.

PMID:
22172969

Supplemental Content

Support Center